- Algernon Pharmaceuticals (OTCQB:BTHCF) reports that its lead drug for inflammatory bowel disease (IBD) is Emoxypine (NP-178), an orally delivered small molecule.
- More news on: Algernon Pharmaceuticals Inc., Healthcare stocks news, Read more ...
home / stock / bthcf / bthcf news
Market Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
Breathtec Biomedical Inc Company Name:
BTHCF Stock Symbol:
Market:
VANCOUVER, British Columbia, May 12, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “ Company ” or “ Algernon ”) a clinical stage pharmaceutical development company announces that NP-120 (Ifenpro...
VANCOUVER, British Columbia, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “ Company ” or “ Algernon ”), a clinical stage pharmaceutical development company, is pleased to announce that Dr. Mar...
VANCOUVER, British Columbia, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “ Company ” or “ Algernon ”), a clinical stage pharmaceutical development company, is pleased to announce that it will...